BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

819 related articles for article (PubMed ID: 19411067)

  • 1. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.
    Lambert JM; Gorzov P; Veprintsev DB; Söderqvist M; Segerbäck D; Bergman J; Fersht AR; Hainaut P; Wiman KG; Bykov VJ
    Cancer Cell; 2009 May; 15(5):376-88. PubMed ID: 19411067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
    Liang Y; Besch-Williford C; Hyder SM
    Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study.
    Benakanakere I; Besch-Williford C; Ellersieck MR; Hyder SM
    Endocr Relat Cancer; 2009 Mar; 16(1):85-98. PubMed ID: 19075036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
    Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P
    Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
    Wiman KG
    Oncogene; 2010 Jul; 29(30):4245-52. PubMed ID: 20498645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.
    Li Y; Mao Y; Brandt-Rauf PW; Williams AC; Fine RL
    Mol Cancer Ther; 2005 Jun; 4(6):901-9. PubMed ID: 15956247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.
    Qiang W; Jin T; Yang Q; Liu W; Liu S; Ji M; He N; Chen C; Shi B; Hou P
    J Biomed Nanotechnol; 2014 Jul; 10(7):1249-58. PubMed ID: 24804545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
    Zache N; Lambert JM; Wiman KG; Bykov VJ
    Cell Oncol; 2008; 30(5):411-8. PubMed ID: 18791272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.
    Bykov VJ; Issaeva N; Shilov A; Hultcrantz M; Pugacheva E; Chumakov P; Bergman J; Wiman KG; Selivanova G
    Nat Med; 2002 Mar; 8(3):282-8. PubMed ID: 11875500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.
    Liang Y; Besch-Williford C; Benakanakere I; Thorpe PE; Hyder SM
    Breast Cancer Res Treat; 2011 Jan; 125(2):407-20. PubMed ID: 20349129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells.
    Rehman A; Chahal MS; Tang X; Bruce JE; Pommier Y; Daoud SS
    Breast Cancer Res; 2005; 7(5):R765-74. PubMed ID: 16168122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells.
    Russo D; Ottaggio L; Penna I; Foggetti G; Fronza G; Inga A; Menichini P
    Biochem Biophys Res Commun; 2010 Nov; 402(2):345-50. PubMed ID: 20946886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249.
    Shi H; Lambert JM; Hautefeuille A; Bykov VJ; Wiman KG; Hainaut P; Caron de Fromentel C
    Carcinogenesis; 2008 Jul; 29(7):1428-34. PubMed ID: 18048389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor Effects of PRIMA-1 and PRIMA-1
    Menichini P; Monti P; Speciale A; Cutrona G; Matis S; Fais F; Taiana E; Neri A; Bomben R; Gentile M; Gattei V; Ferrarini M; Morabito F; Fronza G
    Cells; 2021 Jan; 10(1):. PubMed ID: 33430525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax.
    Wang T; Lee K; Rehman A; Daoud SS
    Biochem Biophys Res Commun; 2007 Jan; 352(1):203-12. PubMed ID: 17113036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRIMA-1 induces caspase-mediated apoptosis in acute promyelocytic leukemia NB4 cells by inhibition of nuclear factor-κB and downregulation of Bcl-2, XIAP, and c-Myc.
    Farhadi E; Safa M; Sharifi AM; Bashash D
    Anticancer Drugs; 2017 Jan; 28(1):51-58. PubMed ID: 27548348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of p53 to limit tumor growth.
    Wang W; El-Deiry WS
    Curr Opin Oncol; 2008 Jan; 20(1):90-6. PubMed ID: 18043262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
    Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
    Ramraj SK; Elayapillai SP; Pelikan RC; Zhao YD; Isingizwe ZR; Kennedy AL; Lightfoot SA; Benbrook DM
    Int J Cancer; 2020 Aug; 147(4):1086-1097. PubMed ID: 31845320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73.
    Rökaeus N; Shen J; Eckhardt I; Bykov VJ; Wiman KG; Wilhelm MT
    Oncogene; 2010 Dec; 29(49):6442-51. PubMed ID: 20818419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.